The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Nxera Pharma Receives Taiwan Regulatory Approval for Insomnia Drug QUVIVIQ

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Nxera Pharma and its partner Holling Bio-Pharma received approval from the Taiwan Food and Drug Administration (TFDA) to market QUVIVIQ for insomnia treatment.

Nxera Pharma and its partner Holling Bio-Pharma have officially received approval from the Taiwan Food and Drug Administration (TFDA) to market QUVIVIQ. The drug, known generically as daridorexant, is indicated for the treatment of insomnia in adult patients. Under the partnership agreement, Holling Bio-Pharma will be responsible for the commercialization and distribution of the product across the Taiwanese market. The launch is currently scheduled for 2026, with the drug being available in both 25mg and 50mg doses. This regulatory milestone represents a significant expansion for Nxera Pharma into the Asian market, opening new revenue streams. Investors view this approval as a positive validation of the drug's clinical profile and the company's long-term growth strategy.